Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Tafinlar
|
| gptkbp:activities |
BRAF inhibitor
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Tafinlar
|
| gptkbp:can_be_used_with |
gptkb:trametinib
|
| gptkbp:clinical_trial |
Phase III
targeted therapy |
| gptkbp:contraindication |
hypersensitivity to dabrafenib
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
dabrafenib
|
| gptkbp:indication |
gptkb:BRAF_V600_E_mutation-positive_tumors
|
| gptkbp:ingredients |
C23 H22 F3 N5 O
|
| gptkbp:interacts_with |
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
8 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:population |
adults
|
| gptkbp:project |
approved
|
| gptkbp:research_areas |
oncology
|
| gptkbp:safety_features |
eye examinations
liver function tests skin examinations |
| gptkbp:side_effect |
gptkb:fandom
gptkb:Insurance_Company gptkb:cutaneous_squamous_cell_carcinoma fatigue headache nausea fever diarrhea rash gastrointestinal perforation joint pain dehydration peripheral neuropathy liver enzyme elevation severe allergic reactions anaphylaxis thrombocytopenia pulmonary embolism venous thromboembolism hyperglycemia neutropenia hypersensitivity reactions severe infections hypophosphatemia cardiac events rhabdomyolysis pyrexia severe skin reactions ocular toxicity musculoskeletal pain hypomagnesemia hypocalcemia fatigue-related events serious skin reactions |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:BRAF_V600_E_mutation
|
| gptkbp:year_created |
gptkb:2013
|